# A Phase I Clinical Trial of XZP-5610 Tablets in Healthy Subjects

> **NCT04913090** · PHASE1 · UNKNOWN · sponsor: **Xuanzhu Biopharmaceutical Co., Ltd.** · enrollment: 112 (estimated)

## Conditions studied

- Nonalcoholic Steatohepatitis (NASH)

## Interventions

- **DRUG:** XZP-5610 Tablet (for Part A)
- **DRUG:** Placebo to match XZP-5610 Tablet (for Part A)
- **DRUG:** XZP-5610 Tablet (for Part B)
- **DRUG:** Placebo to match XZP-5610 Tablet (for Part B)
- **DRUG:** XZP-5610 Tablet （for "Part C1"）
- **DRUG:** XZP-5610 Tablet for "Part C2"

## Key facts

- **NCT ID:** NCT04913090
- **Lead sponsor:** Xuanzhu Biopharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-05-31
- **Primary completion:** 2022-03-04
- **Final completion:** 2022-03-04
- **Target enrollment:** 112 (ESTIMATED)
- **Last updated:** 2021-06-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04913090

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04913090, "A Phase I Clinical Trial of XZP-5610 Tablets in Healthy Subjects". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT04913090. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*